Industry News
New breakthrough for women with advanced cervical cancer, Avastin (bevacizumab) can extend lives
Feb 24, 2014
New data showing cancer treatment Avastin® (bevacizumab) can extend the lives of women with advanced cervical cancer compared to chemotherapy alone has been published in the New England Journal of Medicine. In the last decade the incidence of cervical cancer has risen by approximately 15% in the UK with 2,900 women diagnosed in 2010. Read More
Immune cells regulate blood stem cells
Feb 24, 2014
Researchers in Bern have discovered that, during a viral infection, immune cells control the blood stem cells in the bone marrow and therefore also the body's own defences. The findings could allow for new forms of therapy, such as for bone marrow diseases like leukaemia. Read More
Effective markers of improved patient outcome: MATH, HPV status in HNSCC
Feb 24, 2014
Evaluating next-generation sequencing (NGS) data and associated clinical records of head and neck squamous cell carcinoma (HNSCC) patients from several institutions, made available through The Cancer Genome Atlas (TCGA), showed that combining Mutant-Allele Tumor Heterogeneity (MATH) as a biomarker with the patient's HPV status provides an effective indicator of improved patient outcome, according... Read More
HPV-positive SCCOP patients' recurrence differs from HPV-negative patients
Feb 24, 2014
Patients with HPV-positive squamous cell carcinoma of the oropharynx (SCCOP) had a longer time to development of distant metastasis (DM) after initial treatment, and had more metastatic sites in more atypical locations compared to HPV-negative patients, according to research presented at the 2014 Multidisciplinary Head and Neck Cancer Symposium. Read More
Lower cancer incidence rate in patients with central nervous system disease explained
Feb 24, 2014
Epidemiological studies demonstrate that diseases of the central nervous system such as Alzheimer, Parkinson and schizophrenia protect against cancer. The most remarkable example is Alzheimer's disease, which can reduce the risk of suffering from cancer by up to 50%. Read More
Greater survival rate from recurrent mouth and throat cancers caused by HPV virus
Feb 24, 2014
People with late-stage cancer at the back of the mouth or throat that recurs after chemotherapy and radiation treatment are twice as likely to be alive two years later if their cancer is caused by the human papillomavirus (HPV), new research led by a Johns Hopkins scientist suggests. Read More
During RT for head and neck cancer, humidification of the mouth, throat reduces mucositis, hospital stay
Feb 24, 2014
Patients who received daily humidification of the mouth and throat region beginning from day one of radiation therapy treatment spent nearly 50 percent fewer days in the hospital to manage their side effects, according to research presented at the 2014 Multidisciplinary Head and Neck Cancer Symposium. Read More
Limiting radiation to major salivary glands in head and neck cancer patients
Feb 24, 2014
Avoiding the contralateral submandibular gland during radiation therapy is feasible and safe with advanced stage, node positive head and neck cancers and base of tongue lesions, according to research presented at the 2014 Multidisciplinary Head and Neck Cancer Symposium. Read More
Greater survival rate from recurrent mouth and throat cancers caused by HPV virus
Feb 24, 2014
People with late-stage cancer at the back of the mouth or throat that recurs after chemotherapy and radiation treatment are twice as likely to be alive two years later if their cancer is caused by the human papillomavirus (HPV), new research led by a Johns Hopkins scientist suggests. Read More
Effective markers of improved patient outcome: MATH, HPV status in HNSCC
Feb 24, 2014
Evaluating next-generation sequencing (NGS) data and associated clinical records of head and neck squamous cell carcinoma (HNSCC) patients from several institutions, made available through The Cancer Genome Atlas (TCGA), showed that combining Mutant-Allele Tumor Heterogeneity (MATH) as a biomarker with the patient's HPV status provides an effective indicator of improved patient outcome, according... Read More
Previous Page Next Page